Weiss Multi-Strategy Advisers’s Relmada Therapeutics RLMD Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,000	Closed	-$570K	–	748
2022 Q2	$570K	Buy	30,000 +22,500	+300%	+$491K	0.02%	538
2022 Q1	$202K	Buy	+7,500	New	+$155K	﹤0.01%	628
2021 Q3	–	Sell	-7,043	Closed	-$225K	–	775
2021 Q2	$225K	Buy	+7,043	New	+$245K	﹤0.01%	612
2021 Q1	–	Sell	-8,434	Closed	-$270K	–	809
2020 Q4	$270K	Buy	8,434 +434	+5%	+$14.9K	0.01%	627
2020 Q3	$301K	Buy	+8,000	New	+$309K	0.01%	514
2020 Q2	–	Sell	-9,225	Closed	-$315K	–	607
2020 Q1	$315K	Sell	9,225 -3,775	-29%	-$152K	0.01%	369
2019 Q4	$507K	Buy	+13,000	New	+$395K	0.01%	537

Other funds holding RLMD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Weiss Multi-Strategy Advisers's RLMD Position: Q3 2022 in Review

Weiss Multi-Strategy Advisers sold out of Relmada Therapeutics (RLMD) in Q3 2022, closing a stake of 30,000 shares — an estimated $570K sold.

Weiss Multi-Strategy Advisers first reported a position in RLMD in Q4 2019 and held it in 7 quarters. The position peaked at $570K in Q2 2022. 134 funds tracked by Wall St. Rank hold RLMD as of Q3 2022.

Weiss Multi-Strategy Advisers reported no remaining Relmada Therapeutics position as of Q3 2022 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 30,000 Relmada Therapeutics shares in Q3 2022, an estimated $570K.
Weiss Multi-Strategy Advisers first reported a position in Relmada Therapeutics in Q4 2019 and held it in 7 quarters.
Weiss Multi-Strategy Advisers's Relmada Therapeutics position peaked at $570K in Q2 2022.
134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.